For the Inventor, By the Inventor

Enter inventor name

Cambridge, MA, United States of America

Clark Qun Pan

USPTO Granted Patents = 52 (Patent Applications = 28)

CIPO Patents = 8 (Patent Applications = 9)

EPO Patents = 29 (Patent Applications = 28)

Average Co-Inventor Count = 4.8

ph-index = 11

Forward Citations = 339(Granted Patents)

Forward Citations (Not Self Cited) = 268(Dec 10, 2025)

Location History:

Sudhury, MA (US) (2015)
Castro Valley, CA (US) (2005 - 2016)
Framingham, MA (US) (2016)
Cambridge, MA (US) (2017)
Bridgewater, NJ (US) (2017 - 2020)
Sutton, MA (US) (2017 - 2023)
Lexington, MA (US) (2023)
Sudbury, MA (US) (2010 - 2024)

Company Filing History:

Genzyme Corporation

Bayer Pharmaceuticals Corporation

Bayer Healthcare LLC

4. 3 out of 1,179

Takeda Pharmaceutical Company Limited

5. 2 out of 1,008

Bayer Corporation

Aerovance, Inc.

7. 1 out of 12,160

Bayer Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Shire-nps Pharmaceuticals, Inc.

Genzyme Coporation

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Parathyroid Hormone Variants

Oligosaccharide-Protein Conjugates

Antibody-Drug Conjugation

Glycoengineering

ScFv-Fc Dimers

VEGF Antagonist Compositions

Peptide Analogs

Affinity Purification

Modified IL-4 Mutein

TGF-Beta Antibodies

GLP-1 Receptor Agonists

Human TIMP-1 Antibodies

52 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12291556 - Parathyroid hormone variants (2025-05-06),

2. 12252504 - Oligosaccharide-protein conjugates (2025-03-18),

3. 12110338 - Site-specific antibody-drug conjugation through glycoengineering (2024-10-08),

4. 11976112 - scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity (2024-05-07),

5. 11807690 - Hyperglycosylated binding polypeptides (2023-11-07),

6. 11697690 - Site-specific glycoengineering of targeting moieties (2023-07-11),

7. 11685912 - Affinity purification of glycosidase-cleaving enzymes (2023-06-27),

8. 11660328 - GLP-2 analogs and peptibodies for administration before, during or after surgery (2023-05-30),

9. 11634468 - Parathyroid hormone variants (2023-04-25),

10. 11325971 - scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity (2022-05-10),

11. 11279725 - Oligosaccharide-protein conjugates (2022-03-22),

12. 11186638 - Anti-αβTCR antibody (2021-11-30),

13. 11130816 - Site-specific antibody-drug conjugation through glycoengineering (2021-09-28),

14. 10995148 - Site-specific glycoengineering of targeting moieties (2021-05-04),

15. 10836813 - Fc containing polypeptides with altered glycosylation and reduced effector function (2020-11-17),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide information on inventor Clark Qun Pan for your article.

Title: Unveiling the Inventive Mind of Clark Qun Pan

Introduction:

Clark Qun Pan, a prolific inventor hailing from Cambridge, MA (US), has left an indelible mark on the field of biotechnology with his numerous patents and groundbreaking innovations.

Latest Patents:

With an impressive portfolio of 48 patents, Clark Qun Pan's latest inventions include "Hyperglycosylated Binding Polypeptides" and "Site-specific Glycoengineering of Targeting Moieties." These patents revolutionize the domain of antigen-binding polypeptides and glycan engineering.

Career Highlights:

Throughout his illustrious career, Clark Qun Pan has made significant contributions while working at renowned companies such as Genzyme Corporation and Bayer Pharmaceuticals Corporation. His expertise and dedication have propelled him to the forefront of cutting-edge research and development in the biopharmaceutical industry.

Collaborations:

Collaborating with esteemed coworkers like Huawei Qiu and James E Stefano, Clark Qun Pan has fostered a culture of innovation and excellence. Together, they have synergized their talents to enhance the efficacy and scope of their groundbreaking inventions.

Conclusion:

In conclusion, Clark Qun Pan stands as a shining example of ingenuity and perseverance in the realm of biotechnological innovations. His relentless pursuit of excellence and collaborative spirit continue to inspire and shape the landscape of modern biopharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…